|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for BRPF1 |
 Gene summary |
| Basic gene Info. | Gene symbol | BRPF1 |
| Gene name | bromodomain and PHD finger containing, 1 | |
| Synonyms | BR140 | |
| Cytomap | UCSC genome browser: 3p26-p25 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001003694.1, NM_004634.2, | |
| Description | bromodomain and PHD finger-containing protein 1bromodomain-containing protein, 140kDperegrin | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602410 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000156983 | ||
| HPRD : 03875 | ||
| Vega : OTTHUMG00000097033 | ||
| Protein | UniProt: P55201 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_BRPF1 | |
| BioGPS: 7862 | ||
| Pathway | NCI Pathway Interaction Database: BRPF1 | |
| KEGG: BRPF1 | ||
| REACTOME: BRPF1 | ||
| Pathway Commons: BRPF1 | ||
| Context | iHOP: BRPF1 | |
| ligand binding site mutation search in PubMed: BRPF1 | ||
| UCL Cancer Institute: BRPF1 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0043966 | histone H3 acetylation | 16387653 | GO:0045893 | positive regulation of transcription, DNA-templated | 18794358 |
| Top |
| Ligand binding site mutations for BRPF1 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | E661 | E661K | BLCA | 1 | G1117 | H1116Y | LUAD | 1 | C296 | M295V | LUAD | 1 | P1121 | P1121H | LUSC | 1 | H301 | A299V | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for BRPF1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | G1117 | H1116Y | 0.063960012 | P1121 | P1121H | -1.5124918 | E661 | E661K | -1.0161985 | C296 | M295V | -0.90937673 | H301 | A299V | -0.65584011 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for BRPF1 from PDB |
| Top |
| Differential gene expression and gene-gene network for BRPF1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for BRPF1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for BRPF1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of BRPF1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 5erc | A | C296 | 9F9 | N-[1,3-DIMETHYL-2-OXO-6-(PIPERIDIN-1-YL)-2,3- DIHYDRO-1H-BENZIMIDAZOL-5-YL]-2- METHOXYBENZAMIDE | 4uye | A | E661 | 9F9 | N-[1,3-DIMETHYL-2-OXO-6-(PIPERIDIN-1-YL)-2,3- DIHYDRO-1H-BENZIMIDAZOL-5-YL]-2- METHOXYBENZAMIDE | 4uye | B | E661 | III | Peptide ligand (SER,GLY,ARG,GLY,LYS,GLY,GLY,LYS,GLY,LEU) | 5ffw | B | E661 | 5XD | 4-ETHYL-~{N}-(6-METHOXY-1,3-DIMETHYL-2-OXIDANYLIDENE- BENZIMIDAZOL-5-YL)BENZENESULFONAMIDE | 5ffy | A | E661 | 5XF | ~{N}-(1,3-DIMETHYL-2-OXIDANYLIDENE-6-PYRROLIDIN-1-YL- BENZIMIDAZOL-5-YL)-2-METHOXY-BENZAMIDE | 5fg5 | A | E661 | 5XF | ~{N}-(1,3-DIMETHYL-2-OXIDANYLIDENE-6-PYRROLIDIN-1-YL- BENZIMIDAZOL-5-YL)-2-METHOXY-BENZAMIDE | 5fg5 | B | E661 | 5XE | 4-BROMANYL-~{N}-(6-METHOXY-1,3-DIMETHYL-2- OXIDANYLIDENE-BENZIMIDAZOL-5-YL)-2-METHYL- BENZENESULFONAMIDE | 5fg4 | A | E661 | III | Peptide ligand (LYS,SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG) | 2x4y | C | G1117 P1121 | ZN | ZINC(2+) | 5erc | A | H301 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG) | 2x4w | A | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG,TYR) | 2x4x | A | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS) | 2x4x | C | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO) | 2x4x | E | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS) | 2x4x | G | P1121 | III | Peptide ligand (ALA,ALA,ARG,LYS,SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG,TYR) | 2x4y | A | P1121 | III | Peptide ligand (ALA,ARG,LYS,SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS) | 2x4y | E | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO) | 2x4y | G | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS) | 2x4y | I | P1121 | III | Peptide ligand (ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS) | 2x4y | K | P1121 | III | Peptide ligand (SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG,TYR) | 2x4y | M | P1121 | III | Peptide ligand (ALA,ARG,LYS,SER,ALA,PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS) | 2x4y | O | P1121 | III | Peptide ligand (PRO,ALA,THR,GLY,GLY,VAL,LYS,LYS,PRO,HIS,ARG,TYR) | 3mo8 | A | P1121 |
| Top |
| Conservation information for LBS of BRPF1 |
| Multiple alignments for P55201 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |